Compare · ABVX vs NVO
ABVX vs NVO
Side-by-side comparison of Abivax SA (ABVX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABVX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 23.8x ABVX ($8.05B).
- Over the past year, ABVX is up 1137.1% and NVO is down 42.5% - ABVX leads by 1179.6 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 10 for ABVX).
- NVO has more recent analyst coverage (25 ratings vs 16 for ABVX).
- Company
- Abivax SA
- Novo Nordisk A/S
- Price
- $101.57-3.30%
- $42.94-1.84%
- Market cap
- $8.05B
- $191.82B
- 1M return
- -19.88%
- -6.14%
- 1Y return
- +1137.15%
- -42.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 10
- 11
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABVX
- Abivax SA downgraded by Jefferies with a new price target
- Abivax SA upgraded by Wedbush with a new price target
- SEC Form 6-K filed by Abivax SA
- Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- SEC Form 6-K filed by Abivax SA
- Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
- SEC Form 6-K filed by Abivax SA
- Abivax Announces Results of its May 11, 2026 Annual General Meeting
- Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates